Ticker

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR's Clinical Trials Mini Symposium Phase 1b indication expansion trial is enrolling SOUTH SAN FRANCISCO, Calif.

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months

Shares of Pliant Therapeutics, Inc. (NASDAQ: PLRX - Get Free Report) have been assigned an average rating of "Reduce" from the five brokerages that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to

Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability. Profitability This table compares Dermata Therapeutics and

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from…